Keywords: Phytopharm, Pipeline, Cogane, ALS, Mycogane, Glaucoma, Valuation
Phytopharm “lacking no confidence” in pipeline; will seek partner, say analysts
Article | 01 June 2011
UK-based Phytopharm (LSE: PYM) has reported successful preclinical studies of Cogane (PYM 50028) in Parkinson’s disease levodopa-induced dyskinesia and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
